Settlement And License Agreement Sample Contracts

Settlement and License Agreement (August 9th, 2018)

This confidential agreement (the "Agreement") is made as of the date of full execution hereof (the "Effective Date") by and between Viveve, Inc., a corporation organized and existing under the laws of the State of Delaware, having its principal place of business at 345 Inverness Drive South, Suite 250, Englewood, Colorado ("Viveve"), and ThermiGen LLC and ThermiAesthetics LLC, limited liability companies organized and existing under the laws of the State of Texas, having their principal place of business at at 3131 West Royal Lane, Suite 100, Irving, Texas 75063 (collectively, "ThermiGen"), and Dr. Red Alinsod, an individual having a principal place of business at 31852 Coast Highway, Suite 203, Laguna Beach, California, (collectively with ThermiGen, "Defendants"), each a "Party" and, collectively, the "Parties";

Confidential Settlement and License Agreement (August 8th, 2018)
Settlement and License Agreement (July 31st, 2018)

This Settlement and License Agreement ("Agreement") is made as of January 26, 2018 ("Effective Date") between Apple Inc., a California corporation ("Apple") and Immersion Corporation, a Delaware corporation ("Immersion"). As used herein, "Party" refers to either Immersion or Apple, and "Parties" refers to Immersion and Apple collectively.

Confidential Settlement and License Agreement (May 31st, 2018)

This Confidential Settlement And License Agreement (the "Settlement Agreement") is made effective as of May 25, 2018 (the "Effective Date") by and among

Confidential Settlement and License Agreement (May 11th, 2018)

This Confidential Settlement And License Agreement (the "Settlement Agreement") is made effective as of May 10, 2018 (the "Effective Date") by and among Valeant Pharmaceuticals International, inc., a Canadian corporation with its United States headquarters at 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807 ("Valeant"), SALIX PHARMACEUTICALS, INC., a California corporation with its principal place of business at 8510 Colonnade Center Drive, Raleigh, North Carolina 27615 ("Salix"), PROGENICS PHARMACEUTICALS, INC., a Delaware corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 ("Progenics"), and Wyeth LLC, a Delaware limited liability company with its principal place of business at 235 East 42nd Street, New York, New York 10017 ("Wyeth") (Wyeth, collectively with Valeant, Salix and Progenics, "Plaintiffs") and PAR STERILE PRODUCTS, LLC ("Par Sterile"), a Delaware limited liability company, with a place of business at 6

Settlement and License Agreement (May 11th, 2018)

This Settlement and License Agreement ("Agreement") is made as of January 26, 2018 ("Effective Date") between Apple Inc., a California corporation ("Apple") and Immersion Corporation, a Delaware corporation ("Immersion"). As used herein, "Party" refers to either Immersion or Apple, and "Parties" refers to Immersion and Apple collectively.

Settlement and License Agreement (May 8th, 2018)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is hereby entered into and made effective on January 5, 2018 (the "Effective Date") by and among Teva Pharmaceuticals International GmbH ("Teva"), AlderBio Holdings, LLC ("AlderHoldings") and Alder Biopharmaceuticals, Inc. ("AlderBio"). AlderHoldings and AlderBio are referred to collectively as "Alder". Teva and Alder are referred to herein individually as a "Party" and collectively, as the "Parties."

Settlement and License Agreement (August 2nd, 2017)

This Settlement and License Agreement ("Agreement"), effective April 12, 2017, is entered into by and between BioMarin Pharmaceutical Inc., a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 770 Lindaro Street, San Rafael, California 94901 ("BioMarin"), Merck & Cie, a Swiss corporation having a principal place of business at Im Laternenacker 5, 8200 Schaffhausen, Switzerland ("Merck") (together "Plaintiffs"); and Par Pharmaceutical, Inc. ("Par"), a company organized under the laws of Delaware, having a principal place of business at 300 Tice Boulevard, Woodcliff Lake, NJ 07677. Each of BioMarin, Merck, and Par are individually referred to herein by name or the term "Party" and collectively referred to herein as "Parties."

Kala Pharmaceuticals, Inc. – Settlement and License Agreement (June 23rd, 2017)

This Settlement and License Agreement (including its attachments, this Agreement) is entered into as of October 24, 2014 (Settlement Agreement Effective Date), by and between GrayBug, LLC, a limited liability company organized and existing under the laws of the State of Maryland and having an address of P.O. Box 13043, Baltimore, MD 21203, on behalf of itself and its Affiliates (as defined below) (collectively, GrayBug), and Kala Pharmaceuticals, Inc., a corporation organized and existing under the laws of State of Delaware and having a place of business at 100 Beaver Street, Suite 201, Waltham, MA 02453, on behalf of itself and its Affiliates (collectively, Kala).

Forward Pharma A/S – SETTLEMENT AND LICENSE AGREEMENT Among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S and Each of the Parties Listed on Appendix I Dated as of January 17, 2017 (April 18th, 2017)
SETTLEMENT AND LICENSE AGREEMENT Among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S and Each of the Parties Listed on Appendix I Dated as of January 17, 2017 (February 1st, 2017)

SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") dated as of the Agreement Date (as defined below), among each of the following Parties:

Enzo Biochem, Inc. – Settlement and License Agreement (October 13th, 2016)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and entered into as of the date of the last signature required by this Agreement (the "Effective Date") by and between Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 ("Enzo") and Illumina, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices at 5200 Illumina Way, San Diego, CA 92122 ("Illumina"). Enzo and Illumina are individually referred to herein as a "Party," and collectively as the "Parties."

Enzo Biochem, Inc. – SETTLEMENT and License AGREEMENT (June 8th, 2016)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and entered into as of the date of the last signature required by this Agreement (the "Effective Date") by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 ("Enzo") and Defendant Agilent Technologies, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices at 5301 Stevens Creek Blvd., Santa Clara, CA 95051 ("Agilent"). Enzo and Agilent are individually referred to herein as a "Party," and collectively as the "Parties."

Enzo Biochem, Inc. – Settlement and License Agreement (June 8th, 2016)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and entered into as of May 16, 2016 (the "Effective Date") by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 ("Enzo"), and Defendant Life Technologies Corporation, a corporation organized and existing under the laws of the State of Delaware, having offices at 5791 Van Allen Way, Carlsbad, California, 92008 ("Life"). Enzo and Life are individually referred to herein as a "Party," and collectively as the "Parties."

Confidential Settlement and License Agreement (March 29th, 2016)

This SETTLEMENT AND LICENSE AGREEMENT (the "Agreement") is by and between NNPT, LLC, a Texas limited liability corporation, and SPHERIX INCORPORATED, as Delaware corporation (collectively "Licensor"), and HUAWEI TECHNOLOGIES CO., LTD.; a Chinese company with major business address at Huawei Industrial Base, Bantian, Longgang District, Shenzhen 518129 P.R. China (hereinafter referred as "Huawei") on behalf of itself and all Licensees (each a "Party" and both collectively "Parties"). This Agreement is effective as of September 16, 2015 ("Effective Date").

Vringo – Confidential Settlement and License Agreement (March 10th, 2016)

This Confidential Settlement and License Agreement ("Agreement") is effective as of December 3, 2015 ("Effective Date") between Vringo, Inc, a corporation organized under the laws of Delaware having its principal place of business at 780 Third Avenue, 12th Floor, New York, New York 10017 for itself and on behalf of its Affiliates (individual and together "Vringo") and ZTE Corporation, a corporation organized under the laws of China and having its principal place of business at ZTE Plaza, Keji Road South, Hi-Tech Industrial Park, Nanshan District, Shenzhen, P.R. China, for itself and on behalf of its Affiliates (individually and together "ZTE").

Settlement and License Agreement (November 9th, 2015)

This Settlement and License Agreement (hereinafter referred to as "Agreement") dated as of this 23rd day of October, 2015 (the "Effective Date"), by and among Actavis Laboratories FL, Inc., a company organized and existing under the laws of the State of Florida, having a principal place of business at 4955 Orange Drive, Davie, FL 33314 ("Actavis"), Orexo AB, a company organized and existing under the laws of Sweden, having a principal place of business at Virdings alle 32 A, 05 Uppsala, Sweden SE-751 ("Orexo"), and Galena Biopharma Inc., having a principle place of business at 4640 SW Macadam Avenue, Portland, OR 97239 ("Galena"). Actavis, Orexo and Galena each are sometimes referred to herein as a "Party" and collectively referred to herein as "Parties."

Confidential Settlement and License Agreement (November 6th, 2015)

This Confidential Settlement And License Agreement (the "Settlement Agreement") is made effective as of September 9, 2015 (the "Effective Date") by and among HORIZON PHARMA IRELAND LIMITED, a corporation organized and existing under the laws of Ireland with a principal place of business at Adelaide Chambers, Peter Street, Dublin 8, Ireland ("Horizon Ireland"), HZNP LIMITED, a nonresident Irish company that is a tax resident of Bermuda with a principal place of business at 21 Laffan St., Hamilton, Pembroke, Bermuda HM09 ("HZNP"), and HORIZON PHARMA USA, INC., a corporation organized and existing under the laws of the State of Delaware with a principal place of business at 520 Lake Cook Road, Suite 520, Deerfield, Illinois ("Horizon USA") (collectively, "Plaintiffs") and TARO PHARMACEUTICALS USA, INC, a New York corporation with a principal place of business at 3 Skyline Drive, Hawthorne, New York ("Taro USA") and TARO PHARMACEUTICALS INDUSTRIES, LTD., an Israeli corporation with a princ

Settlement and License Agreement (November 2nd, 2015)

This Settlement and License Agreement ("Agreement"), effective September 14, 2015, is entered into by and between BioMarin Pharmaceutical Inc., a corporation organized and existing under the laws of the State of Delaware, having a principal place of business at 770 Lindaro Street, San Rafael, California 94901 ("BioMarin"), Merck & Cie, a Swiss corporation having a principal place of business at Im Laternenacker 5, 8200 Schaffhausen, Switzerland ("Merck") (together "Plaintiffs"); and Dr. Reddy's Laboratories, Ltd., a company organized under the laws of India, having a principal place of business at 8-2-337, Road No. 3, Banjara Hills, Hyderabad, 500 034, India and its subsidiaries, including Dr. Reddy's Laboratories, Inc., a corporation incorporated under the laws of the State of New Jersey, having its principal place of business at 107 College Road East, Princeton, New Jersey 08540 (collectively "DRL"). Each of BioMarin, Merck, and DRL are individually referred to herein by name or the

Enzo Biochem, Inc. – Settlement and License Agreement (October 13th, 2015)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and entered into as of the date of the last signature required by this Agreement (the "Effective Date") by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 ("Enzo") and Defendant Affymetrix, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices at 3420 Central Expressway, Santa Clara, CA 95051 ("Affymetrix"). Enzo and Affymetrix are individually referred to herein as a "Party," and collectively as the "Parties."

Kala Pharmaceuticals, Inc. – Settlement and License Agreement (September 21st, 2015)

This Settlement and License Agreement (including its attachments, this Agreement) is entered into as of October 24, 2014 (Settlement Agreement Effective Date), by and between GrayBug, LLC, a limited liability company organized and existing under the laws of the State of Maryland and having an address of P.O. Box 13043, Baltimore, MD 21203, on behalf of itself and its Affiliates (as defined below) (collectively, GrayBug), and Kala Pharmaceuticals, Inc., a corporation organized and existing under the laws of State of Delaware and having a place of business at 100 Beaver Street, Suite 201, Waltham, MA 02453, on behalf of itself and its Affiliates (collectively, Kala).

Enzo Biochem, Inc. – Settlement and License Agreement (September 4th, 2015)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and entered into as of July 20, 2015 (the "Effective Date") by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 ("Enzo"), and Defendant Siemens Healthcare Diagnostics Inc., a corporation organized and existing under the laws of the State of California, having offices at 511 Benedict Ave., Tarrytown, NY 10591 ("Siemens"). Enzo and Siemens are individually referred to herein as a "Party," and collectively as the "Parties."

Confidential Settlement and License Agreement (August 7th, 2015)

This Confidential Settlement And License Agreement (the Settlement Agreement) is made effective as of May 6th, 2015 (the Effective Date) by and among HORIZON PHARMA IRELAND LIMITED, a corporation organized and existing under the laws of Ireland with a principal place of business at Adelaide Chambers, Peter Street, Dublin 8, Ireland (Horizon Ireland), HZNP LIMITED, a nonresident Irish company that is a tax resident of Bermuda with a principal place of business at 21 Laffan St., Hamilton, Pembroke, Bermuda HM09 (HZNP), and HORIZON PHARMA USA, INC., a corporation organized and existing under the laws of the State of Delaware with a principal place of business at 520 Lake Cook Road, Suite 520, Deerfield, Illinois (Horizon USA) (collectively, Plaintiffs) and PERRIGO COMPANY, a Michigan corporation with a place of business at 515 Eastern Avenue, Allegan, Michigan 49010 (Perrigo Co.) and PADDOCK LABORATORIES, LLC, a limited liability company organized and existing under the laws of the State

Enzo Biochem, Inc. – Settlement and License Agreement (July 22nd, 2015)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and entered into as of July 20, 2015 (the "Effective Date") by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 ("Enzo"), and Defendant Siemens Healthcare Diagnostics Inc., a corporation organized and existing under the laws of the State of California, having offices at 511 Benedict Ave., Tarrytown, NY 10591 ("Siemens"). Enzo and Siemens are individually referred to herein as a "Party," and collectively as the "Parties."

Enzo Biochem, Inc. – Settlement and License Agreement (July 7th, 2015)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and entered into as of July 2, 2015 (the "Effective Date") by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 ("Enzo"), and Intervenor-Defendant Luminex Corporation, a corporation organized and existing under the laws of the State of Delaware, having offices at 12212 Technology Blvd., Austin, TX 78727 ("Luminex"). Enzo and Luminex are individually referred to herein as a "Party," and collectively as the "Parties."

Eagle Pharmaceuticals, Inc. – Settlement and License Agreement (May 15th, 2015)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is hereby entered into and made effective on February 13, 2015 (the "Effective Date") by and between Cephalon, Inc. ("Cephalon") and Eagle Pharmaceuticals, Inc. ("Eagle"). Cephalon and Eagle are referred to herein individually as a "Party" and collectively, as the "Parties."

Sucampo Pharmaceuticals, Inc. – Settlement and License Agreement (November 7th, 2014)

This SETTLEMENT AND LICENSE AGREEMENT (this "Agreement") is made and effective as of September ___, 2014 (the "Effective Date"), by and between, on the one hand, Sucampo AG and Sucampo Pharmaceuticals, Inc. (collectively, "Sucampo"), R-Tech Ueno, Ltd. ("RTU"), Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals USA, Inc. and Takeda Pharmaceuticals America, Inc. (collectively, "Takeda"), and on the other hand, Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc., Par Pharmaceutical Companies, Inc. (collectively, "Par"). Sucampo, RTU, Takeda, and Par are collectively referred to as the "Parties," and each separately as a "Party."

Settlement and License Agreement (August 6th, 2014)

This Settlement and License Agreement (the "Agreement") is entered into by and between Abbott Diabetes Care Inc., a Delaware corporation having a principal place of business at 1420 Harbor Bay Parkway, Alameda, CA 94502 ("ADC"), and DexCom, Inc., a Delaware corporation having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 ("DexCom"), each of which is referred to as a "Party" and which are collectively referred to as the "Parties," as of the date on which the last of the two Parties signs the Agreement (the "Effective Date").

Settlement and License Agreement (July 30th, 2013)

This SETTLEMENT AND LICENSE AGREEMENT ("Agreement"), is made and entered into as of April 25, 2013 (the "Effective Date"), by and among NuVasive, Inc., a Delaware corporation with its principal place of business in San Diego, California on the one hand, and Medtronic Sofamor Danek USA, Inc., a Tennessee corporation with its principal place of business in Memphis, Tennessee, Warsaw Orthopedic, Inc., an Indiana corporation with its principal place of business in Warsaw, Indiana, Medtronic Puerto Rico Operations Co., a Cayman Islands corporation with its principal place of business in Humacao, Puerto Rico, and Medtronic Sofamor Danek Deggendorf, GmbH a German corporation with its principal place of business in Deggendorf, Germany on the other hand (each individually referred to as "a Party," and collectively referred to as "the Parties").

Opti – Settlement and License Agreement (November 14th, 2012)

THIS SETTLEMENT AND LICENSE AGREEMENT (hereinafter Agreement) is made the 5th day of October 2012, by and between OPTi Inc., a California corporation having its place of business at 1 First Street, Suite 14, Los Altos, CA 94022 (OPTi), Silicon Integrated Systems Corp., a Taiwan corporation with its principal place of business at No. 180, Sec. 2, Gongdaowu Rd., Hsin-Chu, Taiwan 300, Republic of China (SIS Taiwan), acting on behalf of itself and its Subsidiaries, including but not limited to Silicon Integrated Systems Corp., a corporation organized and existing under the laws of the state of California and that maintains a place of business at 838 North Hillview Drive, Milpitas, CA 95035 (SIS America), and SIS HOLDING LIMITED, a Cayman Islands corporation with a registered address at Marguee P5511-PT3 Place, Suite 300, 430 West Bay Road, P.O. Box 30691, Grand Cayman KY1-1203, Cayman Islands (SIS HOLDING LIMITED) (collectively SIS).

NetSpend Holdings, Inc. – Settlement and License Agreement (November 9th, 2012)

This Settlement and License Agreement ("Agreement") is made and entered into as of November 5, 2012 ("Effective Date") by and between Alexsam, Inc., a Texas corporation ("Alexsam"), NetSpend Holdings, Inc., a Delaware corporation ("Holdings"), and NetSpend Corporation, a Delaware corporation ("NetSpend").

Somaxon Pharmaceuticals – Settlement and License Agreement (July 19th, 2012)

This SETTLEMENT AND LICENSE AGREEMENT (this Agreement) is hereby entered into on July 18, 2012 (the Execution Date) by and among Somaxon Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (Somaxon), ProCom One, Inc., a corporation organized under the laws of the State of Texas (ProCom), (Somaxon and ProCom are collectively Plaintiffs), Zydus Pharmaceuticals (USA), Inc., a corporation organized and existing under the laws of the State of New Jersey (Zydus), and Cadila Healthcare Limited, a company organized and existing under the laws of India (Cadila) (Zydus and Cadila are collectively Defendants; each Plaintiff and each Defendant is a Party).

Somaxon Pharmaceuticals – Settlement and License Agreement (July 19th, 2012)

This SETTLEMENT AND LICENSE AGREEMENT (this Agreement) is hereby entered into on July 17, 2012 (the Execution Date) by and among Somaxon Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (Somaxon), ProCom One, Inc., a corporation organized and existing under the laws of the State of Texas (ProCom), (Somaxon and ProCom are collectively Plaintiffs), Mylan Inc. a corporation organized and existing under the laws of the Commonwealth of Pennsylvania, and Mylan Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of West Virginia (Mylan Inc. and Mylan Pharmaceuticals Inc. are collectively Mylan or Defendants; each Plaintiff and each Defendant is a Party).

Somaxon Pharmaceuticals – Settlement and License Agreement (July 19th, 2012)

This SETTLEMENT AND LICENSE AGREEMENT (this Agreement) is hereby entered into on July 17, 2012 (the Execution Date) by and among Somaxon Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (Somaxon), ProCom One, Inc., a corporation organized and existing under the laws of the State of Texas (ProCom), (Somaxon and ProCom are collectively Plaintiffs), Par Pharmaceutical, Inc. a corporation organized and existing under the laws of the State of Delaware, and Par Pharmaceutical Companies, Inc. a corporation organized and existing under the laws of the State of Delaware (Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. are collectively Par or Defendants; each Plaintiff and each Defendant is a Party).

Settlement and License Agreement (May 29th, 2012)

This Settlement and License Agreement (this Agreement) is entered into by and between Endo Pharmaceuticals Inc. (Endo), Teikoku Pharma USA, Inc. (TPU), Teikoku Seiyaku Co., Ltd. (Teikoku Seiyaku, and together with TPU, Teikoku, and collectively with Endo, Endo/Teikoku), on the one hand, and Watson Laboratories, Inc. (Watson), on the other hand. Endo, TPU, Teikoku Seiyaku and Watson are individually referred to herein by name or the term Party and are referred to collectively herein as the Parties. This Agreement is entered into on and is effective as of May 28, 2012 (the Effective Date).